H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating and $65.00 price target on CRISPR Therapeutics (NASDAQ: CRSP).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE